A global, phase 1/2 study of DB-1311/BNT324 (a novel B7H3 ADC) monotherapy in patients with previously treated advanced cervical cancer or platinum-resistant recurrent ovarian cancer: Outcomes by prior treatment

Gynecologic Oncology 2026

View at publisher
Authors: Ira Winer, Bo Gao, Chih-Long Chang, Lucy Corke, Theodore Gourdin, Xiumin Li, Hong Zheng, Xiaojing Dong, Kyaw Thein, Brian S. Henick, Chia-Chi Lin, Y. Ji
+9 more Aaron Elliott Lisberg, Yu Fang, Jenny Furlanetto, Raoul Tibes, Lianghua Fang, Yang Qiu, Rong Shi, Tongsen Zheng, Qi Zhou
DOI: 10.1016/j.ygyno.2026.01.022
Cited by: 1

Fields of Study & Subjects

Boron Compounds in Chemistry PARP inhibition in cancer therapy Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
Gynecologic Oncology
Publisher
Elsevier BV
Volume
208
Pages
S22–S23
Publication date
23 April 2026
Language
EN